{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.43","value":"-3.9"},{"groupId":"OG001","spread":"14.28","value":"-3.3"},{"groupId":"OG002","spread":"25.36","value":"-2.9"}]}],"title":"Week 76 (n=108, 61, 32)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.66","value":"-6.8"},{"groupId":"OG001","spread":"21.88","value":"-2.9"},{"groupId":"OG002","spread":"12.33","value":"-8.2"}]}],"title":"Week 128 (n=79, 47, 18)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"32"}],"units":"Participants"}],"description":"hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.","dispersionType":"Standard Deviation","groups":[{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"4 mg LY3009104 QD - Parts C and D"},{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.\n\nDose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"},{"description":"Received 8 mg LY3009104 QD in Parts A, B and C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"}],"paramType":"MEAN","populationDescription":"All participants who received study drug in Parts C and D and had hsCRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 76 and 128","title":"Mean Change From Baseline to Weeks 76 and 128 in hsCRP","type":"SECONDARY","unitOfMeasure":"mg/L"}